CStone Pharmaceuticals (USD) CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets. The company currently provides several key therapeutic agents. These include Sugemalimab, a monoclonal antibody specifically targeting programmed death-ligand 1 (PD-L1); GAVRETO, an RET inhibitor prescribed for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used in adults with unresectable or metastatic gastrointestinal stromal tumors that carry a PDGFRA exon 18 mutation. CStone's robust product pipeline features promising candidates such as Nofazinlimab, a PD-1 antibody aimed at treating hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor developed for adults experiencing relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor also indicated for hepatocellular carcinoma. Further augmenting its development portfolio are various compounds including CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, all targeting solid tumors, alongside CS5001, which addresses both solid tumors and hematologic malignancies. Established in 2015, CStone Pharmaceuticals maintains its headquarters in Shanghai, China.

CStone Pharmaceuticals (USD) Active

New Bund Times Square, Shanghai, CN, 201203

Stock Price USD

Price Change

Last Dividend USD

CSPHF's stock peer is ASCLF (Ascletis Pharma Inc.)

CSPHF's stock peer is CHIZF (China Traditional Chinese Medicine Holdings Co. Limited)

CSPHF's stock peer is CSBTF (Kuros Biosciences AG)

CSPHF's stock peer is MEOBF (Mesoblast Limited)

CSPHF's stock peer is NURPF (Neuren Pharmaceuticals Limited)

CSPHF's stock peer is ONTTF (Oxford Nanopore Technologies plc)

CSPHF's stock peer is PHMMF (Pharma Mar, S.A.)

CSPHF's stock peer is PPTDF (PeptiDream Inc.)

CSPHF's stock peer is RYHTY (Ryman Healthcare Limited)

CSPHF's stock peer is SNBIF (SanBio Company Limited)

Healthcare Biotechnology

CStone Pharmaceuticals is a biopharmaceutical firm dedicated to discovering, developing, and marketing innovative immuno-oncology and precision medicine therapies. Their primary objective is to fulfill critical medical requirements for cancer patients, both within China and across global markets. The company currently provides several key therapeutic agents. These include Sugemalimab, a monoclonal antibody specifically targeting programmed death-ligand 1 (PD-L1); GAVRETO, an RET inhibitor prescribed for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used in adults with unresectable or metastatic gastrointestinal stromal tumors that carry a PDGFRA exon 18 mutation. CStone's robust product pipeline features promising candidates such as Nofazinlimab, a PD-1 antibody aimed at treating hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor developed for adults experiencing relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor also indicated for hepatocellular carcinoma. Further augmenting its development portfolio are various compounds including CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, all targeting solid tumors, alongside CS5001, which addresses both solid tumors and hematologic malignancies. Established in 2015, CStone Pharmaceuticals maintains its headquarters in Shanghai, China.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand. This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.

2026-06-25 05:44:00

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients in this cohort.

2026-05-31 20:15:00

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the latest preclinical data for three proprietary pipeline assets at the American Association for Cancer Research (AACR) Annual Meeting (from April 17 to 22), including CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC). CStone's Proprietary ADC Technology Platform All three antibody-drug conjugates (ADCs) presented at AACR – CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC) – are developed utilizing CStone's proprietary ADC technology platform, which incorporates the following core features: High Stability & Precise Payload Release: The platform utilizes CStone's proprietary CSL20 linker, a hydrophilic construct designed for enhanced stability in circulation.

2026-04-19 20:15:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions